GSK's Votrient gets first approval in US for kidney cancer
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline's Votrient (pazopanib) has received its first approval worldwide in the US, for the treatment of advanced renal cell carcinoma (RCC), the main form of kidney cancer.